Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
BioVie Inc
BIVI
Healthcare
Biotechnology
BioVie Inc. is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. In neurodegenerative disease, the Company’s drug candidate bezisterim (NE3107) inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the...
associated neuroinflammation and insulin resistance but not extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) homeostatic functions (insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is in the phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:BIVI)
New Post
View:
Posts & Comments
Threaded Posts
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Dec 11, 2024 9:45pm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigatio
Breaking News: $BIVI Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Stockholders to Learn More About the InvestigationNEW YORK, NY
...more
(1312)
•••
Tradinghands
X
View Profile
View Bullboard History
Post by
Tradinghands
on Oct 24, 2024 1:43pm
Still holding up
BIVI has dug itself out of the recent hole so it just shows that patient is needed for returns
(1312)
•••
Tradinghands
X
View Profile
View Bullboard History
Post by
Tradinghands
on Oct 21, 2024 10:02am
75% pop!
This started moving on Friday now huge volume with a 75% spike! Friday was the time to buy
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Oct 21, 2024 10:00am
Quantum BioPharma Files $700M Federal Lawsuit Against CIBC W
News; $BIVI Quantum BioPharma Files $700M Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, for Possible Stock Price Manipulation and Spoofing2024-10-21 09:45:09 ET
...more
(59)
•••
Nibinator
X
View Profile
View Bullboard History
Post by
Nibinator
on Jul 22, 2024 6:55pm
BUY BUY BUY BUY BUY
Acuitas fnb takes 44% OWNERSHIP
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 12, 2024 11:45am
Genetic Technologies and BioVie Interviews to Air on the Red
BREAKING NEWS: $BIVI Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Mar 04, 2024 5:15pm
Why BioVie (BIVI) Shares Are Down 40% | Benzinga
BREAKING NEWS: $BIVI Why BioVie (BIVI) Shares Are Down 40% | BenzingaBioVie Inc (NASDAQ:BIVI) shares are trading lower by 42% to $1.09 during Monday@s session. The company announced the pricing of its
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Mar 01, 2024 10:00am
US Stocks Mixed; Dell Posts Upbeat Results | Benzinga
BREAKING NEWS: $BIVI US Stocks Mixed; Dell Posts Upbeat Results | BenzingaU.S. stocks traded mixed this morning, with the Dow Jones falling around 40 points on Friday.Following the market opening
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 21, 2024 3:45pm
BIOVIE INC. SECURITIES FRAUD NOTICE: Berger Montague Informs
JUST IN: $BIVI BIOVIE INC. SECURITIES FRAUD NOTICE: Berger Montague Informs BioVie Inc. (BIVI) Investors of Securities Fraud LawsuitPhiladelphia, Pennsylvania--(Newsfile Corp. - February 21, 2024) - A
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 09, 2024 4:00pm
STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against
BREAKING NEWS: $BIVI STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against BioVie Inc. (BIVI)Philadelphia, Pennsylvania--(Newsfile Corp. - February 9, 2024) - Nationally recognized law firm
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 02, 2024 9:15pm
BIOVIE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securi
News; $BIVI BIOVIE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Do you want to stay ahead of the markets? See how DealRoom can help.
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product